Your Health, We Care
Release date: 2026-01-27 09:04:48 Recommended: 14
Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor, primarily indicated for the treatment of ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC). Its core mechanism of action lies in inhibiting the activity of abnormal gene fusion proteins, thereby blocking tumor cell proliferation signaling pathways and delaying disease progression. It exhibits particularly significant efficacy in patients with brain metastases and those with drug-resistant mutations.
For tumors harboring ALK gene rearrangement or ROS1 gene fusion, it precisely inhibits the activity of mutant proteins, reducing cancer cell growth and metastasis.
As a third-generation agent, it can overcome drug resistance associated with first-generation (e.g., crizotinib) and second-generation (e.g., alectinib) ALK inhibitors.
It can effectively cross the blood-brain barrier to enter the central nervous system, inhibit intracranial metastatic lesions, and reduce the risk of disease progression in patients with brain metastases.
Clinical data demonstrate that lorlatinib achieves a high control rate for lung cancer brain metastases.
It significantly prolongs progression-free survival (PFS) in clinical trials, with some patients achieving long-term disease stabilization.
It alleviates lung cancer-related symptoms such as cough and dyspnea, improving patients' quality of life.
Patients with ALK-positive advanced NSCLC, especially those who experience disease recurrence after prior treatment with other ALK inhibitors.
ROS1-positive patients (confirmation via genetic testing is required).
Common adverse reactions include hypercholesterolemia, edema, and weight gain. Severe cases may develop pneumonia or cardiac disorders, necessitating close clinical monitoring.
Long-term use may lead to new gene mutations (e.g., ALK L1196M mutation). Treatment regimens should be adjusted based on dynamic genetic testing results.
Concurrent use with certain antiepileptic drugs or antibiotics may impair therapeutic efficacy. Patients must inform their physicians of their complete medication history in advance.
Important Note: Lorlatinib is a prescription medication. Prior to administration, mutation status must be confirmed through genetic testing, and an individualized treatment plan should be formulated under the guidance of a physician. During treatment, regular re-evaluations including imaging scans, blood tests, and genetic status assessments are required to timely adjust the dosage or switch the treatment regimen.
